Sitemap > News > Immunology & Inflammatory Diseases
Displaying 1 - 50 of 531 results
- Positive Phase I Clinical Results for LCP-Tacro
- Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B® in Systemic Lupus Erythematosus
- Cobalis Announces Delay in Reporting of Phase III Trial Results for PreHistin™ in Seasonal Allergic Rhinitis
- Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis
- Anacor Clinical Study of AN2728, A Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
- BioMS Initiates Enrollment In Pivotal U.S. Phase III MS Trial
- Unigene Reports That Oral Calcitonin Phase III Clinical Study for Osteoarthritis Treatment is Initiated
- Aspreva Announces Fast-Track Designation Granted by the FDA for CellCept in Lupus Nephritis
- Regeneron Submits Biologics License Application To U.S. FDA For IL-1 TRAP (RILONACEPT) For Treatment Of CAPS
- Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
- Pivotal phase III trial showed RevoladeTM (eltrombopag) raised platelet counts and reduced bleeding in patients with chronic ITP
- Abbott's HUMIRA (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
- Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
- Pipex Pharmaceuticals’ Oral TRIMESTA Initiates Enrollment of Phase II/III Clinical Trial for Multiple Sclerosis.
- Human Genome Sciences Reports that a Phase 2 Study of Lymphostat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
- Axcan Pharma Initiates MAX-002 Phase III Clinical Trial to Evaluate the Efficacy and Safety of a High-Concentration 1 Gram Mesalamine Suppository
- GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)
- Prexige® study shows significantly less impact on blood pressure than ibuprofen in osteoarthritis patients with controlled hypertension
- Actemra: Roche´s novel rheumatoid arthritis drug shows substantial benefits for patients in OPTION study
- ACTEMRA™ (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to A Current Standard of Care
- REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
- Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia® (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
- Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
- Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
- FDA Accepts REMICADE® (Infliximab) Supplemental Biologics License Application for Inhibition of Structural Damage and Improving Physical Function in Patients With Psoriatic Arthritis
- Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin™ for Multiple Sclerosis
- AstraZeneca Announces Symbicort Is Now Available In The U.S.
- Dynavax Starts HEPLISAV(TM) Phase 3 in Europe; U.S. Study; and Phase 2 in ESRD in Canada
- Vasogen Reports on Outcome of FDA Meeting
- SciClone Initiates Phase 2 Clinical Trial Using SCV-07 to Treat Hepatitis C Patients
- Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
- Isotechnika achieves full enrolment for ISA247 Phase 2b kidney transplant trial
- CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
- NicOx initiates third pivotal naproxcinod phase 3 study
- UCB and Biogen Idec’s oral VLA-4 antagonist (CDP323) enters phase II development for Multiple Sclerosis
- Cytos Biotechnology reports results from phase IIa study with CYT003-QbG10 in patients suffering from atopic dermatitis.
- Anthera Completes Enrollment of "PLASMA" Trial With A-002 and Announces Initiation of new Investigator Study
- Phase III Bronchiectasis Trial Complete
- EMEA approves Kamada’s plans for phase II / III clinical trials of the aerosolized form of AAT for the treatment of Congenital Emphysema
- Genzyme Announces Results of Clinical Trial of Hylastan
- Actemra: latest phase III study shows significant improvement in symptoms of patients with rheumatoid arthritis
- Critical Therapeutics Initiates Phase IV Study Evaluating ZYFLO CR(TM) in Asthma Patients on Inhaled Corticosteroids Whose Symptoms Are Poorly Controlled Printer Friendly Version
- Inspire to Advance Epinastine Nasal Spray to Phase 3
- Barrier Therapeutics Announces Positive Phase 2 Data With Oral Rambazole in Moderate to Severe Psoriasis
- Amira Pharmaceuticals Announces Positive Initial Data from a Phase 1 Study of AM103, A Novel Product Candidate for the Treatment of Respiratory and Cardiovascular Disease
- XOMA Initiates Phase I U.S. Trial in Type 2 Diabetes for XOMA 052, Monoclonal Antibody With Therapeutic Potential in Multiple Inflammatory Diseases
- Can-Fite Reports Results of a Phase IIb Clinical Study in Rheumatoid Arthritis with CF101, an A3 Adenosine Receptor Agonist. The Results Support Further Clinical Development of CF101
- Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
- Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
- Medarex announce that its partner MedImmune has initiated a Phase Ib multi-dose clinical trial of MEDI-545 for the potential treatment of lupus